Founding Member of QLB Bio (Qilu Boston): Head of Biotherapeutics R&D and Business Development. Oversees QLB Bio's therapeutic antibody pipeline, in-license, out-license, and strategic investment;

Founder & the US Site Head of Kelun Pharmaceuticals in Biologics;

Team Leader at Pfizer; Research Fellow at the NCI, NIH;

PhD in Chemical Biology from Nanjing University;

Over 20 years experience in Biotherapeutics R&D & BD; Led and played key roles in over 20 therapeutic antibody programs from early discovery to late clinical development. Broad experience in multiple therapeutic areas, including oncology, immunology, autoimmune, and CVMED. Strong expertise in target identification, therapeutic antibody design, engineering, molecular assessment, PK/PD, CMC, IND filing & BD;

A recipient of many honors and awards, including Young Investigator's Award by the Protein Society; Outstanding Science Award by SER-CAT, APS; and Fellows Award for Research Excellence by the NIH.